Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled time : 12:01 save search
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting
Published: 2021-02-04 (Crawled : 12:01) - globenewswire.com
AVIR | $3.7 0.0% 220K
|
Health Technology
|
| O: 0.52%
H: 2.5%
C: -7.63%
phase 2 trial at-527 set
BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva
Published: 2020-12-21 (Crawled : 12:01) - globenewswire.com
BCRX | $4.44 -1.33% -1.35% 4.7M
|
Health Technology
|
| O: 0.58%
H: 0.75%
C: -4.16%
results positive treatment phase 3 phase 1 phase 2
Metacrine Reports Positive Results from Phase 1 Trial of MET642
Published: 2020-12-17 (Crawled : 12:01) - globenewswire.com
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 4.18%
H: 2.64%
C: -5.19%
results positive results positive trial phase 3 phase 1 phase 2 met642
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
Published: 2020-12-15 (Crawled : 12:01) - globenewswire.com
AVXL | News | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 20.42%
H: 2.08%
C: -4.16%
life science trial phase 2 anavex®2-73 anavex syndros rett syndrome
ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies
Published: 2020-12-07 (Crawled : 12:01) - globenewswire.com
ALXO M | $15.6 -0.89% -0.9% 480K
|
Commercial Services
|
| O: -1.17%
H: 2.55%
C: -2.97%
cancer phase 2 agx148
Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis
Published: 2020-12-03 (Crawled : 12:01) - globenewswire.com
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: -0.6%
H: 4.0%
C: 0.4%
trial treatment phase 2 psoriasis enroll
Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
Published: 2020-12-02 (Crawled : 12:01) - globenewswire.com
CARA | $0.6816 -1.22% -1.23% 350K
|
Health Technology
|
| O: 0.2%
H: 2.31%
C: 1.22%
dermatitis trial phase 2 atopic dermatitis enroll
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.